Be Bio halts hemophilia B cell-editing therapy trial

Be Bio announced that it has terminated its clinical study of a hemophilia B therapy that used gene-editing of a patient’s own cells.

The termination was recorded in a federal clinical-trials registry, and the company did not provide further details on the reasons for the stop.

The move is a setback for Be Bio’s gene-editing program and could delay its progress toward bringing a hemophilia B treatment to market.